Sanofi in agreement with Janssen to develop E. coli the vaccine candidate

-

PARIS (Reuters) - Sanofi on Tuesday announced it had reached an agreement with Janssen, a part of Johnson & Johnson, to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli.

Under the terms of the deal, both parties will co-fund current and future research and development costs. Sanofi will pay $175 million upfront to Janssen, followed by development and commercial milestones.

(Reporting by Tassilo Hummel; Editing by Benoit Van Overstraeten)

2023-10-03T054417Z_1_LYNXNPEJ9204F_RTROPTP_1_SANOFI-FRANCE.JPG urn:newsml:onlinereport.com:20231003:nRTROPT20231003054417LYNXNPEJ9204F Le logo de Sanofi à Lyon OLFRBUS Reuters France Online Report Business News 20231003T054417+0000 20231003T054417+0000